Sample Page
Author:
Zealand Pharma
Posted Date:
April 14, 2026
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
Zealand Pharma
April 14, 2026
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
Zealand Pharma
March 31, 2026
Resolutions from Zealand Pharma’s Annual General Meeting 2026
Zealand Pharma
March 26, 2026
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation
Zealand Pharma
March 24, 2026
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Zealand Pharma
March 19, 2026
Zealand Pharma to participate in upcoming investor conferences in March 2026
Zealand Pharma
March 9, 2026
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity
Zealand Pharma
March 5, 2026
Zealand Pharma convenes its Annual General Meeting 2026
Zealand Pharma
February 19, 2026
Zealand Pharma Announces Financial Results for the Full Year 2025
Zealand Pharma
February 19, 2026
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830
Zealand Pharma
February 18, 2026
Prev
1
2
3
4
Next
